These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 8271477)

  • 1. Antigenic analysis of coxsackievirus B3 with monoclonal antibodies.
    Hu H; Dong D; Tang E; Zhang M; Cao Y
    Jpn J Med Sci Biol; 1993 Apr; 46(2):87-93. PubMed ID: 8271477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal antibodies for study of antigenic variation in coxsackievirus type B4: association of antigenic determinants with myocarditic properties of the virus.
    Cao Y; Schnurr DP; Schmidt NJ
    J Gen Virol; 1984 May; 65 ( Pt 5)():925-32. PubMed ID: 6202831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of conserved and nonconserved epitopes on Coxsackievirus B4: frequency of antigenic change.
    Prabhakar BS; Menegus MA; Notkins AL
    Virology; 1985 Oct; 146(2):302-6. PubMed ID: 2413617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antigenic sites of coxsackie A9 virus inducing neutralizing monoclonal antibodies protective in mice.
    Buttinelli G; Donati V; Ruggeri FM; Joki-Korpela P; Hyypia T; Fiore L
    Virology; 2003 Jul; 312(1):74-83. PubMed ID: 12890622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The isolation and characteristics of monoclonal antibodies to the structural proteins of Coxsackie B5 virus].
    Boss A; Piirsoo A
    Vopr Virusol; 1994; 39(2):80-2. PubMed ID: 8017060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular mimicry, anti-coxsackievirus B3 neutralizing monoclonal antibodies, and myocarditis.
    Gauntt CJ; Arizpe HM; Higdon AL; Wood HJ; Bowers DF; Rozek MM; Crawley R
    J Immunol; 1995 Mar; 154(6):2983-95. PubMed ID: 7533190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T lymphocyte responses in CVB3-induced murine myocarditis.
    Huber S; Polgar J; Moraska A; Cunningham M; Schwimmbeck P; Schultheiss P
    Scand J Infect Dis Suppl; 1993; 88():67-78. PubMed ID: 7685923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hepatitis E virus of different genotypes contains multiple-type antigenic epitopes].
    Deng L; Meng JH; Zhao Y; Zhang HM; Dai X
    Wei Sheng Wu Xue Bao; 2006 Feb; 46(1):120-6. PubMed ID: 16579478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fine specificity and cross-reactivity of monoclonal antibodies to cyclosporine.
    Quesniaux VF; Tees R; Schreier MH; Wenger RM; Van Regenmortel MH
    Mol Immunol; 1987 Nov; 24(11):1159-68. PubMed ID: 2447493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coxsackievirus B4 heterogeneity: effect of passage on neutralization and mortality.
    Hartig PC; Webb SR
    Acta Virol; 1986 Nov; 30(6):475-86. PubMed ID: 2881467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variations in the susceptibility to Coxsackievirus B3-induced myocarditis among different strains of mice.
    Wolfgram LJ; Beisel KW; Herskowitz A; Rose NR
    J Immunol; 1986 Mar; 136(5):1846-52. PubMed ID: 3005402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Preparation and characteristic analysis of monoclonal antibodies against human growth hormone].
    Wang EM
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1989 Feb; 11(1):63-8. PubMed ID: 2475270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High yield production of an inactivated coxsackie B3 adjuvant vaccine with protective effect against experimental myocarditis.
    Fohlman J; Pauksen K; Morein B; Bjare U; Ilbäck NG; Friman G
    Scand J Infect Dis Suppl; 1993; 88():103-8. PubMed ID: 8390713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of experimental murine Coxsackie B3 myocarditis.
    Herzum M; Huber SA; Weller R; Grebe R; Maisch B
    Eur Heart J; 1991 Aug; 12 Suppl D():200-2. PubMed ID: 1655448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mouse strain-related variation as a factor in the pathogenesis of coxsackievirus B3 murine myocarditis.
    Khatib R; Probert A; Reyes MP; Khatib G; Chason JL
    J Gen Virol; 1987 Dec; 68 ( Pt 12)():2981-8. PubMed ID: 2826643
    [No Abstract]   [Full Text] [Related]  

  • 16. Naturally occurring anti-idiotypic antibodies--mechanisms for autoimmunity and immunoregulation?
    Weremeichik H; Moraska A; Herzum M; Weller A; Huber SA
    Eur Heart J; 1991 Aug; 12 Suppl D():154-7. PubMed ID: 1655445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact on routine diagnosis of echovirus infections of intratypic differentiation and antigenic variation in echovirus type 25 studied by using monoclonal antibodies.
    Peigue-Lafeuille H; Fuchs F; Gharabaghi F; Chambon M; Aymard M
    J Clin Microbiol; 1990 Oct; 28(10):2291-6. PubMed ID: 2229354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralization epitope diversity of coxsackievirus B4 isolates detected by monoclonal antibodies.
    Webb SR; Kearse KP; Foulke CL; Hartig PC; Prabhakar BS
    J Med Virol; 1986 Sep; 20(1):9-15. PubMed ID: 2428930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-Coxsackievirus B3 neutralizing antibodies with pathological potential.
    Gauntt CJ; Arizpe HM; Higdon AL; Rozek MM; Crawley R; Cunningham MW
    Eur Heart J; 1991 Aug; 12 Suppl D():124-9. PubMed ID: 1717270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of non-neutralizing monoclonal antibodies in an ELISA for intratypic differentiation of 28 echovirus type 25 clinical isolates.
    Peigue-Lafeuille H; Bailly JL; Aymard M; Fuchs F
    J Virol Methods; 1992 Jan; 36(1):91-9. PubMed ID: 1372613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.